Correlation Engine 2.0
Clear Search sequence regions

  • AXL (8)
  • breast cancer (1)
  • breast neoplasms (1)
  • cancers (2)
  • cell movement (1)
  • humans (1)
  • kinases (2)
  • MERTK (1)
  • metastasis (1)
  • receptor (4)
  • TYRO3 (1)
  • Sizes of these terms reflect their relevance to your search.

    The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro-​tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated its impact on cancer metastasis and drug resistance. Extensive studies on AXL have highlighted its unique characteristics and physiological functions and suggest that targeting of AXL could be beneficial in combination with chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In this mini review, we discuss possible outcomes of AXL targeting either alone or together with other therapeutic agents and emphasize its impact on triple negative breast cancer (TNBC). Copyright © 2021 Elsevier Ltd. All rights reserved.


    Lohit Khera, Sima Lev. Accelerating AXL targeting for TNBC therapy. The international journal of biochemistry & cell biology. 2021 Oct;139:106057

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 34403827

    View Full Text